CXCL8 and prostate cancer: Upregulation of CXCL8 is also a hallmark of the senescence secretory response, known as the senescence-associated secretory phenotype (SASP), which follows senescence induction and has been shown to promote therapeutic resistance in men with prostate cancer [386].